Solar stocks are winners from the presidential debate and we’ve got one primed to run

Solar stocks are winners from the presidential debate and we’ve got one primed to run

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. 1. The S & P 500 erased much of its earlier losses Wednesday as September continued to live up to its reputation as a volatile month. The in-line August consumer … Read more

GLP-1s tested for uses beyond weight loss, diabetes

GLP-1s tested for uses beyond weight loss, diabetes

Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The list of potential health benefits from … Read more

Viking Therapeutics stock jumps on weight loss injection trial plans

Viking Therapeutics stock jumps on weight loss injection trial plans

Weight loss drug concept. Cr | Istock | Getty Images Shares of Viking Therapeutics jumped 16% in premarket trading Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected.  It brings the San Diego-based company one step closer to joining the … Read more

Brain implant Paradromics launches patient registry

Brain implant Paradromics launches patient registry

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Aamir Ahmed Khan, PhD, Principal Electrical Engineer for Paradromics, works on the Transceiver which connects to the brain implants.  Austin based Paradromics is developing a brain-computer interface to aide disabled and non-verbal patients with communication.  Julia Robinson … Read more

Eli Lilly, drugmakers show off weight loss drug data

Eli Lilly, drugmakers show off weight loss drug data

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Eli Lilly, Novo Nordisk and other drugmakers showed off encouraging data … Read more

Amgen could threaten Novo Nordisk, Eli Lilly weight loss drug dominance

Amgen could threaten Novo Nordisk, Eli Lilly weight loss drug dominance

The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival.  Amgen … Read more

Viking Therapeutics weight loss pill shows positive study results

Viking Therapeutics weight loss pill shows positive study results

Alexey Krukovsky | Istock | Getty Images Viking Therapeutics shares jumped more than 10% in premarket trading Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year. The study results add to the excitement around the drugmaker’s … Read more

First NASH liver disease drug is here, more coming

First NASH liver disease drug is here, more coming

3D Illustration of a human liver organ. magicmine | iStock | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for … Read more

Viking Therapeutics emerges as competitor

Viking Therapeutics emerges as competitor

Cr | Istock | Getty Images Biotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market.  Viking is just one of several companies racing to join the growing space. Some analysts say the market could be worth $100 billion by the end … Read more

Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play

Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Inflation relief: The stock market was … Read more